Today: Girls and Reality TV, Stars' Awkward Photos, Hollywood Cradle Robbers
Sorted by: Top Picks

Experimental Drug More Effective than Aspirin in Preventing Repeat Strokes

By BMDblog on  From bigmountaindrugs.com
by Reuters New drug apixaban, although not yet approved by the FDA, studies are indicating promise for the drug to cut clot risk caused by abnormal heartbeat. According to a new study funded by Bristol-Myers Squibb and Pfizer the investigational drug apixaban (Eliquis), appears to be better than aspirin at preventing blood clots in certain patients who have already suffered a stroke a “mini-stroke” due to abnormal heart rhythm. The team of researchers from Canada and Germany, led by Dr...Read Full Story

Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study

By kevinabramson on  From myoptumhealth.com
It's not yet FDA-approved, but apixaban cut clot risk caused by abnormal heartbeat By -- Alan Mozes Share What is this? Twitter Digg Facebook More... EMAIL PRINT RSS   WEDNESDAY, Feb. 1 (HealthDay News) -- An investigational drug called apixaban (Eliquis) appears to be better than aspirin at preventing blood clots in certain patients who have already suffered a stroke or so-called "mini-stroke" due to an abnormal heart rhythm...Read Full Story

Experimental Blood Thinner Given Before Surgery Shows Benefit

By kevinabramson on  From myoptumhealth.com
Cangrelor has potential to reduce clot risk with low bleeding problems in heart patients, study finds By -- Randy Dotinga Share What is this? Twitter Digg Facebook More... EMAIL PRINT RSS   TUESDAY, Jan. 17 (HealthDay News) -- An experimental anti-blood-clotting drug can serve as a replacement for other drugs such as Plavix in the days before heart surgery, a new study has found. The intravenous drug cangrelor appears to...Read Full Story

Apotex pays Sanofi, Bristol damages over Plavix

By jackingram on  From drugdiscovery.pharmaceutical-business-review.com
Apotex has paid Sanofi and Bristol-Myers Squibb Company an amount of $442,209,362 to satisfy the damages ruling of the Plavix (clopidogrel bisulfate) patent infringement case.Read Full Story

Strokes (Practical Clinical Medicine)

By BirdzwRock on  From stroke.goohealthlife.com
Strokes (Practical Clinical Medicine) stroke medicine – below for more information. stroke medicine Strokes (Practical Clinical Medicine) on the button for more stroke medicine information and reviews. eye drops Image by BoristheFrog Stroke Research at Emory University School of Medicine and Grady Memorial Hospital Full story: is.gd — Biomarkers circulating in the bloodstream may serve as a predictive window for recurrent stroke risk and also help doctors...Read Full Story
Editable by Any Member
Indications

Plavix is indicated for:

* Prevention of vascular ischaemic events in patients with symptomatic atherosclerosis
* Acute coronary syndrome without ST-segment elevation, along with aspirin

It is also used, along with aspirin, for the prevention of thromboembolism after placement of intracoronary stent.

Most consensus-based therapeutic guidelines recommend the use of Plavix, over aspirin, in patients requiring antiplatelet therapy but with a history of gastric ulceration, as inhibition of the synthesis of prostaglandins by aspirin can exacerbate this condition. A recent study has shown that in patients with healed aspirin-induced ulcers, however, patients receiving aspirin plus the proton pump inhibitor esomeprazole had a lower incidence of recurrent ulcer bleeding than patients receiving clopidogrel.

Dosage forms

Plavix is marketed as clopidogrel bisulfate, most commonly under the trade name Plavix, as 75 mg oral tablets.

Adverse effects

Serious adverse drug reactions associated with Plavix therapy include:

* Severe neutropenia
* Thrombotic thrombocytopenic purpura
* Hemorrhage - The incidence of hemorrhage may be increased by the co-administration of aspirin.
* Erectile Dyfunction


Source:
http://en.wikipedia.org/wiki/Plavix
Bristol-Myers Squibb receives damages over Plavix caseZenopaBristol-Myers Squibb and Sanofi have received $442.2 million (279.1 million pounds) in damages from Apotex over the Plavix patent infringement case. The payment represents the final phase of the ten-year patent litigation between the two pharmaceutical ...  
From news.google.com ()
Related news:
More perspectives...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29%2C+Bristol-Myers+Squibb+%28BMY%29+Get+%24442.2M+Payment+from+Plavix+Settlement/7147200.html for the full story.  
From streetinsider.com ()
More perspectives...
Sanofi, BMS collect their $444M in Plavix damagesFiercePharmaApotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ($SNY) and Bristol-Myers Squibb ($BMY), as repayment for its premature launch of generic Plavix back in 2006. The payment marks the end of a patent ...  
From news.google.com ()
More perspectives...
Aspirin and Plavix Don't MixdailyRxTaking both clopidogrel (Plavix) and aspirin together does not appear to cut the risk of recurrent deep brain strokes. Research suggests it also increases the risk of bleeding events or dying. Though the American Heart Association endorses both ...Local researchBend Bulletinall 2 news articles »  
From news.google.com ()
Related news:
More perspectives...
A product liability lawsuit has been filed against Bristol-Myers Squibb and Sanofi Aventis, alleging that the manufacturers of the popular blood thinner Plavix lied about the drug’s safety and effectiveness.  The Plavix complaint was filed earlier this ...  
From api.bing.com ()
More perspectives...
As generic for Plavix nears, long-running battle ends By LINDA A. JOHNSON The Associated Press Published Feb 8, 2012 02:24PM MDT Trenton, N.J. • Just three months before the world’s second-best-selling drug gets U.S. generic competition, a company has paid nearly $445 million to finally end a decadelong, twist-filled patent infringement battle with two heavyweight drugmakers over blood thinner Plavix. Apotex Corp., Canada’s biggest...  
From sltrib.com ()
More perspectives...
Nadrick & Cohen, LLP reports that 72 plaintiffs have joined together in a Plavix side effects lawsuit filed against Bristol-Meyers Squibb. Los Angeles, CA, January 27, 2012 – Seventy-two plaintiffs from across the country have joined together in filing a  
From openpr.com ()
More perspectives...
More From Zimbio
Zimbio Entertainment
Copyright © 2012 - Zimbio, Inc. Some rights reserved.
Share
. . .
Follow
. . .